Sagimet Biosciences Inc. (SGMT)

NGM – Real Time Price. Currency in USD

7.65

-0.04 (-0.52%)

At close: May 12, 2026, 4:00 PM EDT

7.65

0.00 (0.00%)

Pre-market: May 13, 2026, 8:37 AM EDT

12.05.2026

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Cumulative cash, cash equivalents and marketable securities expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe acne SAN MATEO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2026, and provided corporate updates.

11.05.2026

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 SAN MATEO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company will present a poster at the 83rd Society for Investigative Dermatology Annual Meeting (SID 2026) on May 15, 2026 showing in vitro data that supports the potential use of FASN inhibitors in acne.

05.05.2026

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

05.05.2026

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

27.04.2026

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced strategic updates regarding its clinical trials.

27.04.2026

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00 per share. The gross proceeds from the offering are expected to be approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering are to be sold by Sagimet. The offering is expected to close on or about April 28, 2026, subject to the satisfaction of customary closing conditions.

27.04.2026

Sagimet Biosciences Provides Strategic and Corporate Updates

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH development to be undertaken only upon securing non-dilutive funding Sagimet to host a KOL event and webcast, April 30 at 2 pm ET SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today provided strategic and corporate updates.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

27.04.2026

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

27.04.2026

Sagimet Biosciences Provides Strategic and Corporate Updates

20.04.2026

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026.

Sagimet Biosciences Inc. (SGMT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Videos

No Data

Press releases

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Videos

No Data

Press releases

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Search stocks

Sagimet Biosciences Inc. (SGMT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Videos

No Data

Press releases

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Videos

No Data

Press releases

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer